Brokers Set Expectations for PRQR Q1 Earnings

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for ProQR Therapeutics in a report issued on Monday, March 16th. HC Wainwright analyst A. Ghosh expects that the biopharmaceutical company will post earnings of ($0.13) per share for the quarter. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ FY2030 earnings at $0.18 EPS.

PRQR has been the subject of several other research reports. Wall Street Zen raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research note on Friday. Oppenheimer assumed coverage on ProQR Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $9.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.80.

ProQR Therapeutics Trading Up 0.6%

PRQR stock opened at $1.77 on Tuesday. The stock has a market cap of $186.49 million, a PE ratio of -3.85 and a beta of 0.21. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $3.10. The company has a 50-day moving average price of $1.63 and a 200 day moving average price of $2.06.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $5.50 million during the quarter, compared to analysts’ expectations of $6.12 million. ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. raised its position in shares of ProQR Therapeutics by 59.6% during the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares in the last quarter. Guggenheim Capital LLC purchased a new position in ProQR Therapeutics in the fourth quarter valued at approximately $35,000. Moody Lynn & Lieberson LLC purchased a new position in ProQR Therapeutics in the fourth quarter valued at approximately $50,000. Invesco Ltd. acquired a new stake in ProQR Therapeutics during the fourth quarter worth approximately $51,000. Finally, Fifth Third Bancorp purchased a new stake in shares of ProQR Therapeutics during the 3rd quarter worth approximately $64,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.